Cell Signaling Technology Logo - Extra Large
查看特别推荐 >>
  1. Products /
  2. Primary Antibodies /
  3. TACI/TNFRSF13B/CD267 (E1D1P) Rabbit Monoclonal Antibody
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TACI/TNFRSF13B/CD267 (E1D1P) Rabbit Monoclonal Antibody #96641

Filter:
  • WB
  • IP
  • IF
  • F

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 30-40
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100
    Immunofluorescence (Immunocytochemistry) 1:800 - 1:3200
    Flow Cytometry (Fixed/Permeabilized) 1:50 - 1:200
    Flow Cytometry (Live) 1:50 - 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    实验步骤

    Specificity / Sensitivity

    TACI/TNFRSF13B/CD267 (E1D1P) Rabbit Monoclonal Antibody recognizes endogenous levels of total TACI/TNFRSF13B/CD267 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human TACI/TNFRSF13B/CD267 protein.

    Background

    Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) and cluster of differentiation 267 (CD267), is a single-pass type III membrane receptor that is highly expressed on the surface of mature innate-like B cells, such as marginal zone and B-1 B cells in mice, and memory B cells in humans (1-3). TACI/TNFRSF13B/CD267 is also expressed on the surface of activated T cells (4), while monocytes and dendritic cells express lower levels of TACI/TNFRSF13B/CD267 primarily intracellularly (5,6). TACI/TNFRSF13B/CD267 is the receptor for soluble ligands BAFF/TNFSF13B and APRIL/TNFSF13 (7,8). Upon ligation, TACI/TNFRSF13B/CD267 recruits tumor necrosis factor receptor–associated factor (TRAF) family members and calcium signal-modulating cyclophilin ligand (CAMLG) in order to activate NFAT, NF-κB, and AP-1 transcriptional programs (9-11). TACI/TNFRSF13B/CD267 is necessary for T cell-independent type II and type I responses (1,12), negative regulation of B cell and T follicular helper cell numbers (13,14), and promotion of class switch recombination in B cells (15). Mutations and aberrant regulation of TACI/TNFRSF13B/CD267 has been associated with cancer, autoimmune diseases, and immunodeficiency disorders (16-18). Multiple isoforms produced by alternative splicing have been identified.
    1. von Bülow, G.U. et al. (2000) Mamm Genome 11, 628-32.
    2. Mantchev, G.T. et al. (2007) J Immunol 179, 2282-8.
    3. Tsuji, S. et al. (2011) Blood 118, 5832-9.
    4. Wang, H. et al. (2001) Nat Immunol 2, 632-7.
    5. Chang, S.K. et al. (2006) Blood 108, 2687-94.
    6. Chang, S.K. et al. (2008) J Immunol 180, 7394-403.
    7. Wu, Y. et al. (2000) J Biol Chem 275, 35478-85.
    8. Yu, G. et al. (2000) Nat Immunol 1, 252-6.
    9. Hymowitz, S.G. et al. (2005) J Biol Chem 280, 7218-27.
    10. Xia, X.Z. et al. (2000) J Exp Med 192, 137-43.
    11. von Bülow, G.U. and Bram, R.J. (1997) Science 278, 138-41.
    12. Ozcan, E. et al. (2009) J Allergy Clin Immunol 123, 1277-86.e5.
    13. Seshasayee, D. et al. (2003) Immunity 18, 279-88.
    14. Ou, X. et al. (2012) Proc Natl Acad Sci U S A 109, 15401-6.
    15. He, B. et al. (2010) Nat Immunol 11, 836-45.
    16. Castigli, E. et al. (2005) Nat Genet 37, 829-34.
    17. Moura, R.A. et al. (2013) J Rheumatol 40, 1293-302.
    18. Abo-Elfadl, M.T. et al. (2020) Cytokine 125, 154790.

    Alternate Names

    CD267; CVID; CVID2; FLJ39942; IGAD2; MGC133214; MGC39952; RYZN; TACI; TNF receptor superfamily member 13B; TNFRSF13B; TNFRSF14B; TR13B; Transmembrane activator and CAML interactor; tumor necrosis factor receptor 13B; Tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor superfamily, member 13B

    Database Links

    UniProt ID: O14836


    Entrez-Gene Id: 23495


    限制使用

    除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。

    专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    Alexa Fluor is a registered trademark of Life Technologies Corporation.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.